NewAmsterdam Pharma Company N.V..
NAMS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-metabolic diseases. Their primary focus is on developing obicetrapib, an oral, low-dose CETP inhibitor. Obicetrapib is being developed as a potent...Show More
Better Health for All
0
No evidence available to assess NewAmsterdam Pharma Company N.V. on Better Health for All.
Fair Money & Economic Opportunity
0
NAMS.US is a late-stage biopharmaceutical company focused on the research and development of therapies for cardio-metabolic diseases.
1
Its core business is not in financial services, lending, or deposit services.
2
Therefore, all KPIs related to financial products, services, and customer financial data are not applicable to the company's operations, as explicitly stated in the rubric's '0' tier definitions.
Fair Pay & Worker Respect
0
No information regarding NAMS.US (NewAmsterdam Pharma Company N.V.) was found in the provided articles. The articles discuss CEO compensation and pay ratios for various other pharmaceutical and medtech companies, as well as S&P 500 companies, but do not contain any specific data points or facts pertaining to NAMS.US for any of the 'Fair Pay & Worker Respect' KPIs.
Fair Trade & Ethical Sourcing
0
No evidence available to assess NewAmsterdam Pharma Company N.V. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-50
NewAmsterdam Pharma has a policy for confidential and anonymous reporting of financial, accounting, and audit matters, including Code of Conduct/Code of Ethics violations, with assurances of non-retaliation.
1
However, there is no evidence of independent investigation processes. The company is restating financial statements for the years ended December 31, 2022, and 2021, and for each of the three years in the period ended December 31, 2022, due to errors in the calculation of net loss per ordinary share, which constitutes a single restatement event.
2
The company's anti-corruption policy includes reporting of suspected violations, including bribery, but lacks clear guidance on facilitation payments and gift thresholds.
Kind to Animals
0
The provided articles discuss the efforts and policies of regulatory bodies, specifically the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), to reduce animal testing and promote New Approach Methodologies (NAMs). The FDA is releasing a roadmap for replacing animal testing, encouraging the use of NAMs data in drug applications, and aims to spare thousands of animals annually.
1
However, none of the articles provide specific, factual evidence regarding NewAmsterdam Pharma Company N.V.'s (NAMS.US) own animal testing policies, volumes, use of alternative testing methods, certifications, or any other animal welfare-related practices or initiatives.
No War, No Weapons
0
No evidence available to assess NewAmsterdam Pharma Company N.V. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles, including financial reports and corporate updates, do not contain specific data or metrics related to NewAmsterdam Pharma Company N.V.'s planet-friendly business practices.
1
Multiple articles explicitly state that sustainability data is currently unavailable for the company.
2
Industry-level reports were provided but did not contain company-specific information for assessment, therefore no KPIs could be scored.
3
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding NAMS.US's performance on any of the KPIs related to Respect for Cultures & Communities.
1
The articles discuss general pharmaceutical industry topics or unrelated medical conditions, with no information pertaining to NAMS.US's community engagement, cultural impact, or related policies.
2
Safe & Smart Tech
0
NewAmsterdam Pharma's privacy policy, last updated October 2024, states that it processes data only as necessary and retains it according to legal requirements.
1
The company explicitly states compliance with GDPR.
2
Users are granted rights to access, rectify, erase, restrict processing, object to processing, and data portability, with the ability to withdraw consent.
3
The company also mentions proactive patching of known vulnerabilities as part of its information technology protocols.
4
Zero Waste & Sustainable Products
0
The provided article discusses Sanofi's eco-design approach and related metrics, but contains no information relevant to NAMS.US or its performance against any of the 'Zero Waste & Sustainable Products' KPIs.
1